Study to Evaluate the AIO-001 in Healthy Participants

Respiratory Disease Clinical Trial

Official title: Open-Label, Single Dose, Parallel Group, Phase 1 Study in Healthy Volunteers Evaluating Safety, Tolerability, Pharmacokinetics, and Immunogenicity AIO-001 Administered by Injections

Status Not yet recruiting

Clinical Trial Summary

This goal of the open-label single dose study is to evaluate and compare the safety, tolerability, pharmacokinetic (PK), and immunogenicity of AIO-001 using two different formulations in 16 healthy volunteers.

Clinical Trial Description

This is an open-label single dose, parallel group, 24-week, Phase 1 study in 16 healthy participants. The study is designed to evaluate and compare the safety, tolerability, PK, and immunogenicity of AIO-001 using two different formulations (Formulation A and Formulation B) in 16 healthy volunteers (8 receiving each formulation). The study will include a screening visit from Day -28 to Day -2. Eligible participants will be admitted to the clinical site on Day -1 and will be confined until completion of the assessments on Day 3. Participants will return to the clinical site for outpatient visits for study assessments and laboratory tests. ;

Related Conditions & MeSH terms

• Respiration Disorders
• Respiratory Disease
• Respiratory Tract Diseases

• NCT number: NCT06170827
• Study type: Interventional
• Source: Syneos Health
• Contact: Reza Pishva
• Phone: 61(0)410 308 134
• Email: reza.pishva@syneoshealth.com
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 19, 2023
• Completion date: December 20, 2024